Menu

Investors

SEC Filings

SEC Filings

Filing date Form Description View
June 2, 2020 4

Statement of changes in beneficial ownership of securities

View HTML
May 21, 2020 DEFA14A

Additional proxy soliciting materials - definitive

View HTML
May 12, 2020 424B5

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

View HTML
May 12, 2020 8-K

Report of unscheduled material events or corporate event

View HTML
May 11, 2020 424B5

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

View HTML
May 5, 2020 8-K

Report of unscheduled material events or corporate event

View HTML
May 5, 2020 10-Q

Quarterly report which provides a continuing view of a company's financial position

EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
April 24, 2020 CT ORDER

CT ORDER

View HTML
April 23, 2020 DEF 14A

Official notification to shareholders of matters to be brought to a vote ("Proxy")

View HTML
April 23, 2020 DEFA14A

Additional proxy soliciting materials - definitive

View HTML

Data provided by Kaleidoscope.

Print Page
Email Page
Contact IR
Email Alerts
Tear Sheet

Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142

Driving Directions

+1 617.871.2098  phone
+1 617.871.2099  fax

Contact Us